Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 3/2011

Open Access 01-09-2011 | Mini Review

The role of Tau protein in resistance to paclitaxel

Authors: Marta Smoter, Lubomir Bodnar, Renata Duchnowska, Rafał Stec, Bartłomiej Grala, Cezary Szczylik

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2011

Login to get access

Abstract

Resistance to taxanes, related to limited efficacy of systemic therapy in cancer patients, is multifactorial. Among mechanisms of resistance to taxanes, those related to microtubule-associated proteins (MAP), including protein Tau, are of great importance. Protein Tau (50–64 kD) binds to beta-tubulin in the same place as paclitaxel. In preclinical studies, low expression of Tau in cancer cells was associated with increased sensitivity to paclitaxel. High expression of Tau protein in ER-positive breast cancers indicates resistance to taxane-containing chemotherapy and sensitivity to hormonal treatment. This article reviews current knowledge on predictive value of protein Tau in response to taxanes. Better understanding of its role may facilitate patients selection to this sort of treatment and lead to treatment optimization.
Literature
1.
Amos LA, Löwe J (1999) How Taxol stabilises microtubule structure. Chem Biol 6:65–69CrossRef
2.
Wang LG, Liu XM, Kreis W, Budman DR (1999) The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44:355–361PubMedCrossRef
3.
Ling YH, Tornos C, Perez-Soler R (1998) Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem 273:18984–18991PubMedCrossRef
4.
Ferlini C, Cicchillitti L, Raspaglio G et al (2009) Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res 69:6906–6914PubMedCrossRef
5.
Bodnar L, Wcisło G, Miedzińska-Maciejewska M, Szczylik C (2004) Docetaksel i paklitaksel: porównanie ich budowy, farmakologii oraz mechanizmów oporności. Współczesna Onkol 9:435–446
6.
Gadducci A, Cosio S, Muraca S, Genazzani AR (2002) Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications. Eur J Gynaecol Oncol 23:390–396PubMed
7.
Stordal B, Pavlakis N, Davey R (2007) A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev 33:688–703PubMedCrossRef
8.
Buttita F, Marchetti A, Gadducci A et al (1997) p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 75:230–235CrossRef
9.
Wahl AF, Donaldson KL, Fairchild C et al (1996) Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72–79PubMedCrossRef
10.
Lavarino C, Pilotti S, Oggionni M et al (2000) p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18:3936–3945PubMed
11.
Nogales E (2001) Structural insight into microtubule function. Annu Rev Biophys Biomol Struct 30:397–420PubMedCrossRef
12.
Perez EA (2009) Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 8:2086–2095PubMedCrossRef
13.
Dziedzic-Gocławska A (2000) Ruch komórek i ich organelli. In: Moskalewski S, Sawicki W (eds) Fizjologia molekularna komórki. Akademia Medyczna w Warszawie, Warsaw, pp 220–262
14.
Burkhart CA, Kavallaris M, Band Horwitz S (2001) The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 1471:O1–O9PubMed
15.
Kavallaris M, Kuo DY, Burkhart CA et al (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. Clin Invest 100:1282–1293CrossRef
16.
Sève P, Reiman T, Lai R et al (2007) Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 60:27–34PubMedCrossRef
17.
Sève P, Reiman T, Isaac S et al (2008) Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. Anticancer Res 28:1161–1167PubMed
18.
Sève P, Lai R, Ding K et al (2007) Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 13:994–999PubMedCrossRef
19.
Ferrandina G, Zannoni GF, Tinelli G et al (2006) Class III B-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 12:2774–2779PubMedCrossRef
20.
Aoki D, Oda Y, Hattori S et al (2009) Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res 15:1473–1480PubMedCrossRef
21.
Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein factor essential for microtubule assembly. PNAS 72:1858–1862PubMedCrossRef
22.
23.
Kar S, Fan J, Smith MJ, Goedert M, Amos LA (2003) Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J 22:70–77PubMedCrossRef
24.
Dye RB, Fink SP, Williams RC (1993) Taxol-induced flexibility of microtubules and its reversal by MAP-2 and Tau. J Biol Chem 268:6847–6850PubMed
25.
Andre F, Hatzis C, Anderson K et al (2007) Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 13:2061–2067PubMedCrossRef
26.
Rouzier R, Rajan R, Wagner P et al (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102:8315–8320PubMedCrossRef
27.
Tanaka S, Nohara T, Iwamoto M et al (2009) Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Cancer Chemother Pharmacol 64:341–346PubMedCrossRef
28.
Shao YY, Kuo KT, Hu FC et al (2010) Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Jpn J Clin Oncol 40:286–293PubMedCrossRef
29.
Mimori K, Sadanaga N, Yoshikawa Y et al (2006) Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment. Br J Cancer 94:1894–1897PubMedCrossRef
30.
Pentheroudakis G, Kalogeras KT, Wirtz RM et al (2009) Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat 116:131–143PubMedCrossRef
31.
Pusztai L, Jeong JH, Gong H et al (2009) Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol 27:4287–4292PubMedCrossRef
Metadata
Title
The role of Tau protein in resistance to paclitaxel
Authors
Marta Smoter
Lubomir Bodnar
Renata Duchnowska
Rafał Stec
Bartłomiej Grala
Cezary Szczylik
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 3/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-011-1696-7

Other articles of this Issue 3/2011

Cancer Chemotherapy and Pharmacology 3/2011 Go to the issue

Original Article

Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients

Original Article

Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice

Original Article

Preoperative radiotherapy with capecitabine and mitomycin C in locally advanced rectal carcinoma

Original Article

Involvement of RhoA and RalB in geranylgeranyltransferase I inhibitor-mediated inhibition of proliferation and migration of human oral squamous cell carcinoma cells

Clinical Trial Report

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

Original Article

Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits